Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | UBE2M | P61081 | 3/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26185568 | 0.90 | NPC1 (0.41) | MAPK14HPGDSROCK2TYRLMNA | |
| SCHEMBL26567620 | 0.82 | ROCK2 (0.39) | DYRK1AHPGDSROCK2LMNAUBE2M | |
| SCHEMBL26568062 | 0.81 | HPGDS (0.36) | DYRK1AHPGDSROCK2LMNAUBE2M | |
| SCHEMBL26567589 | 0.79 | CHRM4 (0.38) | DYRK1AHPGDSROCK2LMNAUBE2M | |
| SCHEMBL26567751 | 0.79 | DYRK1A (0.38) | DYRK1AROCK2LMNAUBE2MDCUN1D1 | |
| SCHEMBL26567893 | 0.77 | KCNK3 (0.40) | DYRK1AHPGDSROCK2LMNAUBE2M | |
| SCHEMBL26567573 | 0.77 | LMNA (0.40) | DYRK1AROCK2LMNAUBE2MDCUN1D1 | |
| SCHEMBL26567915 | 0.76 | CSNK1E (0.39) | DYRK1AHPGDSROCK2LMNAUBE2M | |
| SCHEMBL26567649 | 0.76 | NPC1 (0.38) | DYRK1AHPGDSROCK2LMNAHDAC4 | |
| SCHEMBL26567483 | 0.76 | PCSK9 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1I3, NR1H4 | MAPK14 3568/4885DYRK1A 4673/4885HPGDS 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.